IGF1 and neoplasm: In the human subcutaneous PDAC xenografts, treatment of tumor-bearing mice with nab-paclitaxel and BMS-754807, an inhibitor of IGF signaling, caused significant antitumor effects as mono- and combination therapy of these agents demonstrated additive effects.